Search results
Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal
Bloomberg via Yahoo Finance· 11 hours ago(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing...
Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases...
Benzinga via Yahoo Finance· 11 hours agoThe terms of the agreement include: A co-exclusive license to co-commercialize Novavax’s current...
Novavax strikes $1.2 billion deal with Sanofi in major turnaround
Axios· 8 hours agoDriving the news: Novavax will receive an upfront payment of $500 million and up to $700 million in...
Novavax’s 99% Surge Gives ‘Rib-Crunching’ Squeeze to Shorts
Bloomberg via Yahoo Finance· 5 hours ago(Bloomberg) -- Novavax Inc.’s record one-day gain is forcing some short sellers betting against the...
Novavax Inc (NVAX) Q1 2024 Earnings: Navigating Challenges with Strategic Partnerships and Cost ...
GuruFocus.com via Yahoo Finance· 8 hours agoFinancial Performance Analysis The first quarter saw Novavax generating $93.855 million in total revenue, a notable increase from $80.951 million in the prior year...end of ...
Why Novavax Stock More Than Doubled Today
Motley Fool via Yahoo Finance· 8 hours agoThe Stock Advisor service has more than quadrupled the return... has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy....
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine...
WKRN Nashville· 19 hours ago...Agreements and in India, Japan and South Korea where Novavax has existing partnership agreements); a sole license to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines while Novavax retains the right to and is developing its own COVID-19-Influenza Combination ...
Novavax Inc (NVAX) Q1 2024 Earnings: Navigating Challenges with
Guru Focus· 8 hours agoThe company, a prominent player in the biotechnology sector focusing on the development of vaccines, reported a net loss of $147.55 million with a loss per share of $1.05.
UPDATE 3-Novavax signs COVID-19 license deal with Sanofi, revokes 'going concern' warning
Reuters via Yahoo Finance· 19 hours agoNovavax on Friday removed doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for COVID-19 vaccines< ...
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
CBS 47 Fresno· 19 hours agoAnnounces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop ...